Saperconazole in the treatment of systemic and subcutaneous mycoses.
In a 2-year period, 30 patients with culture-proven mycoses (chromoblastomycosis, sporotrichosis, and paracoccidioidomycosis) were treated with the new orally administered triazole, saperconazole (SPZ) (R66905). The daily dose varied from 100 to 200 mg. All patients responded to treatment; the mean time required to heal the lesions and convert the cultures to negative was 3.5 months for sporotrichosis, 4.6 for paracoccidioidomycosis, and 9.0 for chromoblastomycosis. Evaluation by a scoring system indicated that 36.6% of the patients achieved complete resolution of the pretherapy abnormalities, while the remaining (63.3%) experienced major improvement. No collateral effects were reported; there were no bone-marrow or liver toxicities. SPZ is an effective drug for the treatment of the above-mentioned mycoses and appears to be suitable for the control of chromoblastomycosis.
Franco
L
L
Corporacion para Investigaciones Biologicas (CIB), Hospital Pablo Tobon Uribe, Medellin, Colombia.
Gomez
I
I
Restrepo
A
A
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001393:Azoles / Q000008:administration & dosage / Q000627:therapeutic use*; D002214:Capsules; D002648:Child; D002862:Chromoblastomycosis / Q000188:drug therapy*; D003881:Dermatomycoses / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010229:Paracoccidioidomycosis / Q000188:drug therapy*; D012074:Remission Induction; D013174:Sporotrichosis / Q000188:drug therapy*; D013997:Time Factors
D000935:Antifungal Agents; D001393:Azoles; D002214:Capsules; C060571:saperconazole